CA2771232A1 - Purification of vwf for increased removal of non-lipid enveloped viruses - Google Patents

Purification of vwf for increased removal of non-lipid enveloped viruses Download PDF

Info

Publication number
CA2771232A1
CA2771232A1 CA2771232A CA2771232A CA2771232A1 CA 2771232 A1 CA2771232 A1 CA 2771232A1 CA 2771232 A CA2771232 A CA 2771232A CA 2771232 A CA2771232 A CA 2771232A CA 2771232 A1 CA2771232 A1 CA 2771232A1
Authority
CA
Canada
Prior art keywords
cation exchange
exchange resin
protein
vwf
wash buffer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2771232A
Other languages
English (en)
French (fr)
Inventor
Artur Mitterer
Meinhard Hasslacher
Christa Mayer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Baxter Healthcare SA
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43063204&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2771232(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter Healthcare SA, Baxter International Inc filed Critical Baxter Healthcare SA
Publication of CA2771232A1 publication Critical patent/CA2771232A1/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/755Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/18Ion-exchange chromatography

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2771232A 2009-08-20 2010-08-20 Purification of vwf for increased removal of non-lipid enveloped viruses Pending CA2771232A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23557009P 2009-08-20 2009-08-20
US61/235,570 2009-08-20
PCT/US2010/046180 WO2011022657A1 (en) 2009-08-20 2010-08-20 Purification of vwf for increased removal of non-lipid enveloped viruses

Publications (1)

Publication Number Publication Date
CA2771232A1 true CA2771232A1 (en) 2011-02-24

Family

ID=43063204

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2771232A Pending CA2771232A1 (en) 2009-08-20 2010-08-20 Purification of vwf for increased removal of non-lipid enveloped viruses

Country Status (18)

Country Link
US (1) US9315560B2 (show.php)
EP (1) EP2467399B2 (show.php)
JP (1) JP5838159B2 (show.php)
KR (1) KR101894600B1 (show.php)
CN (2) CN106008697B (show.php)
AU (1) AU2010284116B9 (show.php)
BR (1) BR112012003802B1 (show.php)
CA (1) CA2771232A1 (show.php)
DK (1) DK2467399T3 (show.php)
ES (1) ES2562256T5 (show.php)
HU (1) HUE026907T2 (show.php)
IN (1) IN2012DN01849A (show.php)
MX (1) MX2012002129A (show.php)
NZ (1) NZ598249A (show.php)
PL (1) PL2467399T3 (show.php)
PT (1) PT2467399E (show.php)
SG (2) SG178478A1 (show.php)
WO (1) WO2011022657A1 (show.php)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
HRP20130414T1 (en) 2008-10-21 2013-06-30 Baxter International Inc. Lyophilized recombinant vwf formulations
MX386767B (es) * 2012-06-21 2025-03-19 Takeda Pharmaceuticals Co Filtración de virus de medio de cultivo celular.
US9902942B2 (en) 2013-02-22 2018-02-27 Agency For Science, Technology And Research Chromatographic purification of virus preparations with negatively charged particles
KR20170010895A (ko) * 2014-06-06 2017-02-01 옥타파마 아게 인자 ⅷ 및 폰 빌레브란트 인자 펩티드를 포함하는 조제
PL3158055T3 (pl) 2014-06-13 2020-03-31 Csl Limited Ulepszone wytwarzanie rekombinowanego czynnika von Willebranda w bioreaktorze
AU2018321131B2 (en) 2017-08-23 2024-06-13 Csl Behring Gmbh Method for virus filtration of von Willebrand Factor
BR112020019057A2 (pt) * 2018-03-21 2020-12-29 Baxalta Incorporated Método para obter uma composição, e, composição farmacêutica.
AU2023232562A1 (en) 2022-03-08 2024-09-05 Equashield Medical Ltd Fluid transfer station in a robotic pharmaceutical preparation system

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941763A (en) * 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
JPS62502589A (ja) 1985-04-11 1987-10-08 ザ・チヤイルドレンズ・メデイカル・センタ−・コ−ポレ−シヨン フオン・ビルブラント因子
US5728553A (en) * 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
AT406373B (de) * 1997-02-27 2000-04-25 Immuno Ag Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie
AT405403B (de) * 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
AT405485B (de) 1997-05-28 1999-08-25 Immuno Ag Eine das vwf-propeptid enthaltende pharmazeutische präparation
US6531577B1 (en) 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
ES2292682T3 (es) * 1998-05-06 2008-03-16 Genentech, Inc. Purificacion de anticuerpos mediante cromatografia de intercambio ionico.
DK1835938T3 (da) 2004-12-27 2013-11-04 Baxter Int Polymer-von Willebrand-faktor-konjugater

Also Published As

Publication number Publication date
EP2467399B1 (en) 2015-11-11
HUE026907T2 (en) 2016-07-28
ES2562256T5 (es) 2023-07-20
KR20120065342A (ko) 2012-06-20
ES2562256T3 (es) 2016-03-03
SG178478A1 (en) 2012-04-27
AU2010284116B2 (en) 2015-02-12
JP5838159B2 (ja) 2015-12-24
BR112012003802A2 (pt) 2016-11-22
CN106008697A (zh) 2016-10-12
EP2467399B2 (en) 2023-02-01
US20110092681A1 (en) 2011-04-21
PL2467399T3 (pl) 2016-05-31
DK2467399T3 (en) 2017-01-23
AU2010284116B9 (en) 2015-03-26
MX2012002129A (es) 2012-06-08
IN2012DN01849A (show.php) 2015-08-21
NZ598249A (en) 2014-04-30
CN106008697B (zh) 2020-08-04
WO2011022657A1 (en) 2011-02-24
US9315560B2 (en) 2016-04-19
SG10201408106WA (en) 2015-01-29
PT2467399E (pt) 2016-03-18
KR101894600B1 (ko) 2018-09-03
AU2010284116A1 (en) 2012-03-08
CN102482341A (zh) 2012-05-30
BR112012003802B1 (pt) 2022-10-25
JP2013502434A (ja) 2013-01-24
EP2467399A1 (en) 2012-06-27

Similar Documents

Publication Publication Date Title
AU2010284116B9 (en) Purification of VWF for increased removal of non-lipid enveloped viruses
KR101804136B1 (ko) 응고 인자 viii을 정제하는 방법
JP7458980B2 (ja) アルキルグリコシドによるタンパク質精製およびウイルス不活化
AU2010319425A1 (en) Von Willebrand factor (vWF)-containing preparations, and methods, kits, and uses related thereto
KR20040111351A (ko) 단백질 제제의 안정화
WO2008104372A1 (en) Method for the purification of recombinant blood coagulation factor ix enriched in sulfated and/or phosphorylated molecules
KR101842412B1 (ko) 형질전환 인자 ⅶ 의 정제 방법
US6034222A (en) Method for the separation of recombinant pro-factor IX from recombinant factor IX
US8058411B2 (en) Method for producing mature VWF from VWF pro-peptide
JP7818898B2 (ja) クロマトグラフィー法によるvwfとvwfプロペプチドの分離
AU2015201483A1 (en) Purification of VWF for Increased Removal of Non-Lipid Enveloped Viruses
HK1230206A1 (en) Purification of vwf for increased removal of non-lipid enveloped viruses
HK1170744A (en) Purification of vwf for increased removal of non-lipid enveloped viruses
HK1230206B (zh) 纯化vwf以增加非-脂质包封的病毒的去除
HK40050722A (en) Separation of vwf and vwf propeptide by chromatographic methods
HK1144577B (en) Method for producing mature vwf from vwf pro-peptide

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150807

EEER Examination request

Effective date: 20150807

EEER Examination request

Effective date: 20150807

EEER Examination request

Effective date: 20150807

EEER Examination request

Effective date: 20150807

EEER Examination request

Effective date: 20150807

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240726

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241217

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241217

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D171 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: FINAL ACTION SENT TO PAB

Effective date: 20250430